top of page
  • Writer's pictureEscalate Life Sciences

COVID-19 tracker: Bharat's nasal vaccine booster wins authorization in India

Regulatory authorities in India endorsed Bharat Biotech's nasal vaccine booster.

Plus, Pfizer CEO Albert Bourla was reprimanded for prior comments on his company's children's COVID-19 vaccine before the shot won a regulatory authorization in the U.K.

India’s regulatory authorities have granted emergency use authorization to Bharat Biotech’s booter dose of its nasal COVID vaccine, dubbed iNCOVACC. The vaccine is India’s first nasal spray against COVID-19 and was approved as a primary dose in September. The third dose is approved for adults only, the Hindu BusinessLine reports.

Ashish Jha, President Joe Biden’s pandemic response coordinator, said on ABC’s “This Week” that it will be “very, very difficult” for China to contain COVID-19 through its Zero Covid strategy, recommending instead that the country makes sure everybody, particularity the elderly, receive a vaccine. Jha added that lockdowns and the Zero Covid strategy will be “very difficult” to sustain, Bloomberg reports. White House medical advisor Anthony Fauci added that the prolonged lockdown “really doesn’t make public health sense.”

Speaking of Fauci, the infectious disease expert also said in an interview with NBC’s “Meet the Press” that between 300 and 400 people are still dying of COVID-19 every day and that the country is “certainly” still in a pandemic. The uptake of the latest vaccine booster was less than 15%, he added.

After Pfizer’s CEO Albert Bourla said in an interview last December that the benefits are in favor of vaccinating children against COVID-19, UK pharmaceutical watchdog the Prescription Medicines Code of Practice Authority (PMCPA) received a complaint from parent campaign group UsForThem. After a review, PMCPA concluded that the company did breach the country's pharma code in several ways, including making unsubstantiated claims.

See full history Here

Published By Zoey Becker, Kevin Dunleavy, Fraiser Kansteiner, Angus Liu

Nov 28, 2022 11:02am

in Fierce Pharma

1 view0 comments
bottom of page